https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Gedatolisib Doublet, Triplet Regimens Improve PFS in Patients With PIK3CA Wild-Type HR+/HER2– Breast Cancer

Gedatolisib Doublet, Triplet Regimens Improve PFS in Patients With PIK3CA Wild-Type HR+/HER2– Breast Cancer

Emerging trial results reveal gedatolisib significantly enhances progression-free survival (PFS) in advanced HR+/HER2- breast cancer.

administrator

Related Articles